Cooper Financial Group Purchases 184 Shares of Eli Lilly and Company (NYSE:LLY)

Cooper Financial Group boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,164 shares of the company’s stock after purchasing an additional 184 shares during the period. Cooper Financial Group’s holdings in Eli Lilly and Company were worth $546,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Oxler Private Wealth LLC raised its holdings in Eli Lilly and Company by 0.4% in the 1st quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock valued at $2,078,000 after buying an additional 24 shares during the last quarter. Missouri Trust & Investment Co lifted its holdings in shares of Eli Lilly and Company by 3.2% during the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock worth $266,000 after purchasing an additional 24 shares during the period. Silvercrest Asset Management Group LLC increased its holdings in Eli Lilly and Company by 0.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 4,331 shares of the company’s stock valued at $1,487,000 after purchasing an additional 25 shares during the period. Cora Capital Advisors LLC raised its position in Eli Lilly and Company by 2.8% during the 1st quarter. Cora Capital Advisors LLC now owns 956 shares of the company’s stock worth $328,000 after purchasing an additional 26 shares during the last quarter. Finally, Sittner & Nelson LLC lifted its holdings in Eli Lilly and Company by 2.7% during the 1st quarter. Sittner & Nelson LLC now owns 1,003 shares of the company’s stock worth $344,000 after buying an additional 26 shares during the period. 81.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Credit Suisse Group upped their target price on Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, August 9th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a report on Tuesday, August 8th. Jefferies Financial Group upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their price target for the stock from $408.00 to $615.00 in a report on Tuesday, August 8th. BMO Capital Markets boosted their price objective on Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. Finally, JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $510.00 to $600.00 and gave the stock an “overweight” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $532.78.

Insider Activity at Eli Lilly and Company

In other news, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the transaction, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CAO Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $546.51, for a total value of $327,906.00. Following the sale, the chief accounting officer now directly owns 5,378 shares in the company, valued at approximately $2,939,130.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,010,309 shares of company stock worth $21,095,701,670. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Down 2.7 %

Shares of Eli Lilly and Company stock opened at $575.66 on Friday. The company has a market capitalization of $546.47 billion, a P/E ratio of 80.06, a price-to-earnings-growth ratio of 2.47 and a beta of 0.32. The stock has a fifty day simple moving average of $510.09 and a 200 day simple moving average of $435.73. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $601.84. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The company had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. During the same quarter in the prior year, the company posted $1.25 earnings per share. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, sell-side analysts anticipate that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 62.87%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.